Your support fuels our research to #EndALS! Donate Now


Neurimmune NI-204 / TDI 200

The misfolding of the antioxidant enzyme superoxide dismutase1 (SOD1) in motor neurons may contribute to ALS. A human-derived monoclonal antibody directed to misfolded SOD1, Neurimmune’s NI-204 aims to reduce the accumulation of misfolded SOD1 within motor neurons in people with ALS and thereby slow the progression of the disease.


Type: Protein Biologic
Stage: Preclinical
Status: Active
Sponsor: ALS Therapy Development Institute & Neurimmune

TDI Says:

Targeting misfolded SOD1, according to a growing number of studies, could be important in both the treatment of sporadic and familial forms of ALS. We look forward to further evaluating these antibodies as a potential treatment for the disease.

Learn More

  • SOD1 Off ALS

    Emerging strategies targeting misfolded SOD1 aim to slow or stop the spread of ALS - even in sporadic disease.

  • Charting the course of ALS

    A new map may help scientists design potential medicines that stop ALS in its tracks.

  • Antibodies for sALS?

    PALS that produce antibodies targeting misfolded SOD1 appear to live significantly longer according to a small study.

Published Results

Comment on this Topic

(All comments are moderated before they appear here.)